• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Unproven (Off-Label) Treatments

Unproven (Off-Label) Treatments

Background

Given the lack of approved and effective treatments for ALS, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety and in all of them; there is no proof of benefit. Furthermore, these treatments are often extremely expensive, capitalizing on desperation and hope, and many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Examples of such treatments include, but are not limited to; stem cell clinics, holistic/naturopathic/homeopathic/traditional medicine, and dietary or physical therapy regimens.

Resources like ALSUntangled (www.alsuntangled.com) can be valuable for balanced, open-access information about such alternative treatments and www.clinicaltrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

A forthcoming ALSUntangled podcast/review entitled ‘“ten red flags”-things to be wary of in alternative or off-label products’ provides helpful guide to the warning signs to look out for in an advertised potential treatment. Click here for the “ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved/unproven/off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like www.clinicaltrials.gov are encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there was anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

 

International Alliance of ALS/MND Associations
June 2020

 


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Len Johnrose, England

    Len Johnrose, England

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Jon Newsome, USA

    Jon Newsome, USA

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Mirca Bersani, Italy

    Mirca Bersani, Italy
    MircaBersani

  • Jason Goodman, USA

    Jason Goodman, USA

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Ali Var, Turkey

    Ali Var, Turkey

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Purningam Jacob, India

    Purningam Jacob, India

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Yolanda Armendariz, Mexico

    Yolanda Armendariz, Mexico

  • John Dinon, Australia

    John Dinon, Australia

  • Alex, Argentina

    Alex, Argentina

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Timmy, Belgium

    Timmy, Belgium

  • Hollister

    Hollister
    hollister

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • Magdalena Ayala Rodríguez, Mexico

    Magdalena Ayala Rodríguez, Mexico

  • Enzo Maccarrone, Italy

    Enzo Maccarrone, Italy

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Olga, Argentina

    Olga, Argentina

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login